Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines
暂无分享,去创建一个
[1] Rebecca Zerzan. "Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis". , 2005, Discovery medicine.
[2] L. Wilkinson. Immunity , 1891, The Lancet.
[3] M. Duddy,et al. Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1 , 2004, The Journal of Immunology.
[4] C. Farina,et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. , 2004, Brain : a journal of neurology.
[5] Clare Baecher-Allan,et al. Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.
[6] B. Trapp. Pathogenesis of multiple sclerosis: The eyes only see what the mind is prepared to comprehend , 2004, Annals of neurology.
[7] M. Barnett,et al. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.
[8] R. Simon,et al. Expansion and Functional Relevance of High-Avidity Myelin-Specific CD4+ T Cells in Multiple Sclerosis , 2004, The Journal of Immunology.
[9] K. Toyka,et al. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate , 2004, Journal of Neuroimmunology.
[10] K. Rajewsky,et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] Arthur A. Vandenbark,et al. TCR Peptide Therapy in Human Autoimmune Diseases , 2001, Neurochemical Research.
[12] H. Weiner. Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis , 2004 .
[13] A. Achiron,et al. T-cell vaccination in multiple sclerosis. , 2004, Autoimmunity Reviews.
[14] Mark M. Davis,et al. T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.
[15] M. Sela,et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Hohlfeld,et al. T-cell-mediated autoimmunity - Novel techniques to characterize autoreactive T-cell receptors , 2003 .
[17] D. Gilden,et al. Single-Cell Repertoire Analysis Demonstrates that Clonal Expansion Is a Prominent Feature of the B Cell Response in Multiple Sclerosis Cerebrospinal Fluid 1 , 2003, The Journal of Immunology.
[18] C. Polman,et al. New and emerging treatment options for multiple sclerosis , 2003, The Lancet Neurology.
[19] Lawrence Steinman,et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis , 2003, Nature Biotechnology.
[20] M. Zhan,et al. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype , 2003, Journal of Neuroimmunology.
[21] G. Martino,et al. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. , 2003, Current opinion in neurology.
[22] Lawrence Steinman,et al. Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year , 2003, The Journal of experimental medicine.
[23] M. Kapsenberg,et al. Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1 , 2003, The Journal of Immunology.
[24] H. Hartung,et al. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. , 2003, Trends in pharmacological sciences.
[25] R. Hohlfeld,et al. Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases , 2003, Annals of neurology.
[26] Leonard C. Harrison,et al. Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity , 2003, Nature Reviews Immunology.
[27] J. Bach. Regulatory lymphocytes: Regulatory T cells under scrutiny , 2003, Nature Reviews Immunology.
[28] N. Hellings,et al. T cell vaccination in multiple sclerosis patients with autologous CSF‐derived activated T cells: results from a pilot study , 2003, Clinical and experimental immunology.
[29] L. Peltonen,et al. Aire regulates negative selection of organ-specific T cells , 2003, Nature Immunology.
[30] C. Farina,et al. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis , 2002, Journal of Neurology.
[31] R. Hohlfeld,et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.
[32] Arne Svejgaard,et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis , 2002, Nature Immunology.
[33] A. Bar-Or,et al. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. , 2002, Clinical immunology.
[34] H. Neumann,et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases , 2002, Trends in Neurosciences.
[35] Massimo Filippi,et al. MRI techniques to monitor MS evolution: The present and the future , 2002, Neurology.
[36] F. Barkhof,et al. Antibody‐mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial , 2002, Annals of neurology.
[37] H. Hartung,et al. New concepts in the immunopathogenesis of multiple sclerosis , 2002, Nature Reviews Neuroscience.
[38] P. Brown,et al. Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.
[39] C. Farina,et al. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients , 2002, Journal of Neuroimmunology.
[40] V. Rivera,et al. T cell vaccination in multiple sclerosis: results of a preliminary study , 2002, Journal of Neurology.
[41] D S Goodin,et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines , 2002, Neurology.
[42] Manjit,et al. Neurology , 1912, NeuroImage.
[43] W. Brück,et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? , 2002, Brain : a journal of neurology.
[44] H. Link,et al. Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis , 2001, Journal of Neuroimmunology.
[45] H. McFarland,et al. CD4+CD28- costimulation-independent T cells in multiple sclerosis. , 2001, The Journal of clinical investigation.
[46] Pablo Villoslada,et al. Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates , 2001, European journal of immunology.
[47] J. Goverman,et al. A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis , 2001, The Journal of experimental medicine.
[48] Roland Martin,et al. Immunotherapy of multiple sclerosis: Where are we? Where should we go? , 2001, Nature Immunology.
[49] M. A. Curotto de Lafaille,et al. Regulatory T cells in spontaneous autoimmune encephalomyelitis , 2001, Immunological reviews.
[50] P. Fontoura,et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. , 2001, Immunity.
[51] H. Wekerle,et al. Myelin Antigen-Specific CD8+ T Cells Are Encephalitogenic and Produce Severe Disease in C57BL/6 Mice1 , 2001, The Journal of Immunology.
[52] H. Lassmann,et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. , 2001, Immunity.
[53] R. Moss,et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. , 2001, Journal of neuroscience research.
[54] M. Sela,et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® , 2001, Journal of Neuroimmunology.
[55] C. Farina,et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. , 2001, Brain : a journal of neurology.
[56] C. Farina,et al. Mechanisms of action of glatiramer acetate in multiple sclerosis , 2001, Neurology.
[57] Massimo Filippi,et al. European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.
[58] C. Lucchinetti,et al. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.
[59] H. Neumann,et al. Anti‐inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration , 2001, European journal of immunology.
[60] R. Martin,et al. Mechanisms of immunomodulation by glatiramer acetate , 2000, Neurology.
[61] H. Wekerle,et al. Myelin oligodendrocyte glycoprotein‐DNA vaccination induces antibody‐mediated autoaggression in experimental autoimmune encephalomyelitis , 2000, European journal of immunology.
[62] J. Antel,et al. NBI‐5788, an altered MBP83‐99 peptide, induces a T‐helper 2–like immune response in multiple sclerosis patients , 2000, Annals of neurology.
[63] H. Weiner,et al. Oral tolerance, an active immunologic process mediated by multiple mechanisms. , 2000, The Journal of clinical investigation.
[64] I. Catz,et al. Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients , 2000, Multiple sclerosis.
[65] A. Evans,et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.
[66] J. Frank,et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.
[67] Hans Lassmann,et al. Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction , 2000, The Journal of experimental medicine.
[68] G. Barger,et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years , 2000, Multiple sclerosis.
[69] L. Weiner,et al. T cell vaccination in secondary progressive multiple sclerosis , 2000, Journal of Neuroimmunology.
[70] C. Farina,et al. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[71] L. Steinman. Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. , 2000, Journal of autoimmunity.
[72] J. Parisi,et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.
[73] Jingwu Z. Zhang,et al. Preferential Recognition of TCR Hypervariable Regions by Human Anti-Idiotypic T Cells Induced by T Cell Vaccination1 , 2000, The Journal of Immunology.
[74] J. Krieger,et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. , 2000, The Journal of clinical investigation.
[75] R. Hohlfeld,et al. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. , 2000, Brain : a journal of neurology.
[76] N. Chiorazzi,et al. Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.
[77] T. Olsson,et al. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[78] P. Stinissen,et al. Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations , 2000, Journal of Neuroimmunology.
[79] Roland Martin,et al. Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7 , 1999, Journal of Neuroimmunology.
[80] S. Baranzini,et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. , 1999, Journal of immunology.
[81] L. Fugger,et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor , 1999, Nature Genetics.
[82] P. Stinissen,et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. , 1999, Journal of autoimmunity.
[83] H. Wekerle,et al. Gene transfer into CD4+ T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses , 1999, Nature Medicine.
[84] E. Meinl,et al. Concepts of viral pathogenesis of multiple sclerosis. , 1999, Current opinion in neurology.
[85] S. Schmidt. Candidate autoantigens in multiple sclerosis , 1999, Multiple sclerosis.
[86] Roland Martin,et al. Molecular mimicry and multiple sclerosis: Degenerate T‐cell recognition and the induction of autoimmunity , 1999, Annals of neurology.
[87] H. Weiner. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[88] H. Garren,et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. , 1999, Journal of immunology.
[89] Irun R. Cohen,et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.
[90] M. Sela,et al. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 , 1998, Journal of Neuroimmunology.
[91] Y. Qin,et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. , 1998, The Journal of clinical investigation.
[92] F. Zipp,et al. Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. , 1998, Brain : a journal of neurology.
[93] H. Wekerle. The viral triggering of autoimmune disease , 1998, Nature Medicine.
[94] H. Lassmann,et al. Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis , 1998, The Journal of experimental medicine.
[95] L. Chess,et al. T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[96] J S Wolinsky,et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.
[97] C. June,et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. , 1998 .
[98] D. Gilden,et al. Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.
[99] D. E. Anderson,et al. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. , 1998, Journal of immunology.
[100] S. Reingold,et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.
[101] V. Tuohy,et al. Treatment of Experimental Autoimmune Encephalomyelitis with Genetically Modified Memory T Cells , 1997, The Journal of experimental medicine.
[102] Larry R. Smith,et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide , 1997, Journal of Neuroimmunology.
[103] Larry R. Smith,et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations , 1997, Journal of Neuroimmunology.
[104] G. Nolan,et al. Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis , 1997, The Journal of experimental medicine.
[105] I. Catz,et al. The effect of intrathecal MBP synthetic peptides containing epitope P85VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis , 1997, Journal of the Neurological Sciences.
[106] R. Hohlfeld,et al. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.
[107] H. Lassmann,et al. Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. , 1997, The American journal of pathology.
[108] M. Sela,et al. Cop 1 as a candidate drug for multiple sclerosis. , 1997, Journal of neural transmission. Supplementum.
[109] D. Bourdette,et al. Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial , 1996, Nature Medicine.
[110] B. Becher,et al. Immunotherapy for multiple sclerosis: From theory to practice , 1996, Nature Medicine.
[111] I. Cohen,et al. Suppressive vaccination with DNA encoding a variable region gene of the T–cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity , 1996, Nature Medicine.
[112] R. Doms,et al. Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. , 1996, Journal of immunology.
[113] D. Hafler,et al. TCR usage in human and experimental demyelinating disease. , 1996, Immunology today.
[114] A. Vandenbark,et al. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential , 1996, Journal of neuroscience research.
[115] P. Allen,et al. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. , 1996, Annual review of immunology.
[116] D. Wraith. Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. , 1995, International archives of allergy and immunology.
[117] H. Thoenen,et al. Gene transfer through the blood–nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis , 1995, Nature Medicine.
[118] P. Stinissen,et al. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis , 1995, The Lancet.
[119] E. Meinl,et al. Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys. , 1995, International immunology.
[120] J. Wolinsky. Copolymer 1 , 1995, Neurology.
[121] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[122] R. Ferrante,et al. In healthy primates, circulating autoreactive T cells mediate autoimmune disease. , 1994, The Journal of clinical investigation.
[123] D. Bourdette,et al. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. , 1994, Journal of immunology.
[124] D. Bourdette,et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. , 1994, Journal of immunology.
[125] H. Weiner,et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis , 1994, The Journal of experimental medicine.
[126] K. Rajewsky,et al. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. , 1993, The EMBO journal.
[127] Norbert,et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. , 1993, The Journal of clinical investigation.
[128] D. Hafler,et al. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. , 1993, Science.
[129] E. Sercarz,et al. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. , 1993, Immunology today.
[130] A. Begovich,et al. Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis , 1993, Nature.
[131] H. Weiner,et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. , 1993, Science.
[132] R. Hohlfeld,et al. Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor β chain from a myelin basic protein‐specific T cell clone , 1993 .
[133] M. Sela,et al. A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis , 1991, Neurology.
[134] Eric O Long,et al. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis , 1991, The Journal of experimental medicine.
[135] L. Kappos,et al. Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals , 1990, Neurology.
[136] L. Kappos,et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[137] H. Weiner,et al. T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis , 1990, Nature.
[138] A. Begovich,et al. Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients , 1990, Nature.
[139] R J Albertini,et al. T cells responsive to myelin basic protein in patients with multiple sclerosis. , 1990, Science.
[140] L. Steinman,et al. The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.
[141] D. Carlo,et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. , 1989, Science.
[142] A. Vandenbark,et al. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis , 1989, Nature.
[143] R. Hohlfeld. Neurological autoimmune disease and the trimolecular complex of T‐lymphocytes , 1989, Annals of neurology.
[144] H. Wekerle,et al. T cell receptor β chain usage in myelin basic protein‐specific rat T lymphocytes , 1989 .
[145] A. Ben-nun,et al. Regulatory circuits in autoimmunity: recruitment of counter‐regulatory CD8+ T cells by encephalitogenic CD4+ T line cells , 1988, European journal of immunology.
[146] L. Hood,et al. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy , 1988, Cell.
[147] H. Mcdevitt,et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention , 1988, Cell.
[148] H. Wekerle,et al. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic TT cell interactions , 1988, Nature.
[149] H. Lassmann,et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. , 1988, The American journal of pathology.
[150] H. Weiner,et al. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. , 1987, Journal of immunology.
[151] M. Oldstone. Molecular mimicry and autoimmune disease , 1987, Cell.
[152] S. Wassertheil-Smoller,et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. , 1987, The New England journal of medicine.
[153] H. Wekerle,et al. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. , 1985, Journal of immunology.
[154] B. Zweiman,et al. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. , 1983, Cellular immunology.
[155] I. Cohen,et al. Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein , 1981, Nature.
[156] I. Cohen,et al. Vaccination against autoimmune encephalomyelitis (EAE): Attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line , 1981, European journal of immunology.
[157] I. Cohen,et al. The rapid isolation of clonable antigen‐specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis , 1981, European journal of immunology.